Lantern Pharma Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Lantern Pharma Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Revenue & Gross Profit
Revenue0.000.000.000.000.00
Cost of Revenue0.008.450.000.000.00
Gross Profit0.00-8.450.000.000.00
Operating Expenses
Research & Development16.1311.898.607.572.24
Selling, General & Administrative6.095.985.835.023.66
Operating Expenses22.2217.8814.4312.595.91
Operating Income-22.22-17.88-14.43-12.59-5.91
Other Income/Expense
Interest Income0.740.770.200.070.00
Interest Expense0.000.000.000.000.00
Other Income/Expense1.441.15-0.030.160.00
Income
Income Before Tax-20.78-15.96-14.26-12.36-5.91
Income Tax Expense0.000.000.000.000.00
Net Income-20.78-15.96-14.26-12.36-5.91
Net Income - Continuous Operations-20.78-15.96-14.26-12.360.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-22.20-17.86-14.42-12.58-5.90
EBIT-20.78-17.88-14.43-12.59-5.91
Depreciation & Amortization0.020.010.010.010.00
Earnings Per Share
Basic EPS-1931.00-1.00-1.00-1.00-1.00
Diluted EPS-1931.00-1.00-1.00-1.00-1.00
Basic Shares Outstanding10.7610.8410.8510.904.30
Diluted Shares Outstanding10.7610.8410.8510.904.30